VYGR - NASDAQ
Voyager Therapeutics, Inc.
$3.59
+1.1%Voyager Therapeutics, Inc., a gene therapy company, focuses on the development of treatments and next-generation platform technologies. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1 clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD102 for the treatment of amyotrophic lateral sclerosis; VY-HTT01 for Huntington's disease; VY-FXN01 for Friedreich's ataxia; and Tau program for the treatment of tauopathies, including Alzheimer's disease, progressive supranuclear palsy, and frontotemporal dementia, as well as for spinal muscular atrophy. The company has collaboration and license agreements with Neurocrine Biosciences, Inc., Pfizer Inc., and Novartis Pharma, A.G. for the research, development, and commercialization of adeno-associated virus gene therapy products. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.
At a Glance
Live SnapshotVoyager Therapeutics, Inc. Cash Conversion Engine
Cash Flow Quality Analysis
FCF Conversion Rate
Excellent cash generation. The company converts earnings to cash at or above 100%, indicating high-quality earnings.
CapEx Intensity
Asset-light business model. Low capital requirements leave more cash available for shareholders and growth investments.
FCF Growth Trend
Significant FCF decline raises concerns. Urgent review needed of operational performance and capital allocation.
Working Capital Impact
Moderate working capital outflow. Typical for growing businesses, but ensure it's supporting revenue growth, not inefficiency.
Cash Flow Quality Insight
Working capital strain: Significant cash tied up in operations. Monitor receivables collection, inventory turns, and payment terms to optimize cash conversion cycle.
Voyager Therapeutics, Inc. Cash Flow Statement
VYGR • NASDAQ
| Voyager Therapeutics, Inc. Cash Flow Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
OPERATING ACTIVITIES | |||||||||||||
-119.7M | -65M | 132.3M | -46.4M | -71.2M | 36.7M | -43.6M | -88.3M | -70.7M | -40.2M | -29.7M | -16.3M | -7.7M | |
4.1M | 4.7M | 4.4M | 6.2M | 5.2M | 3.8M | 2.8M | 2.1M | 1.6M | 612K | 600K | 184K | 0.0 | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -3.6M | -2.2M | -24K | 696K | 452K | 0.0 | 0.0 | |
14.8M | 14.8M | 11.2M | 9.3M | 11.3M | 14.9M | 15.6M | 15.7M | 9.2M | 6.3M | 4M | 425K | 0.0 | |
-2.8M | -4.7M | -3.4M | -2.1M | -2.1M | -7.7M | -996K | 1.4M | 674K | 2.9M | 9.8M | 3.3M | 2M | |
-28.8M | 34.9M | -66.6M | 20.5M | 3.3M | -144.5M | 78.4M | 55.4M | -2.1M | -12.8M | 56.1M | 477K | 182K | |
-132.5M | -15.3M | 77.9M | -12.5M | -53.5M | -96.7M | 48.7M | -15.9M | -61.4M | -42.5M | 41.3M | -11.9M | -5.5M | |
INVESTING ACTIVITIES | |||||||||||||
-2.6M | -3.5M | -3.3M | -2.5M | -1.6M | -12.1M | -7.7M | -4.3M | -4M | -5M | -1M | -3M | (0.0) | |
(0.0) | (0.0) | (138.4M) | (0.0) | (0.0) | (0.0) | (172K) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
-133.9M | -465.7M | -224M | -54.8M | -15.1M | -70.4M | -494.2M | -333.2M | -147.3M | -112.4M | -220.4M | (0.0) | (0.0) | |
262M | 374.3M | 85.6M | 50M | 82.6M | 195.5M | 411.3M | 364M | 147.6M | 165.1M | 26.7M | 0.0 | 0.0 | |
0.0 | 0.0 | -138.4M | 0.0 | 0.0 | 0.0 | -82.8M | 30.8M | 304K | -421K | -193.7M | -314K | 0.0 | |
(125.4M) | -94.9M | -141.6M | -7.3M | (65.9M) | (113M) | -90.5M | (26.5M) | -3.7M | (47.3M) | -194.8M | -3.3M | (0.0) | |
FINANCING ACTIVITIES | |||||||||||||
816K | 114M | 33.6M | 1.1M | 612K | 3.2M | 77.6M | 0.0 | 58M | 0.0 | 104.8M | 80K | 0.0 | |
(0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (860K) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 3.4M | 4.7M | 1.9M | 514K | 73M | 22.1M | 5.7M | |
816K | 114M | 33.6M | 1.1M | 612K | 3.2M | 81M | 4.7M | 59.9M | 514K | 177.7M | 22.1M | 5.7M | |
CASH FLOW SUMMARY | |||||||||||||
0.0 | 0.0 | 0.0 | 264K | 0.0 | -1M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
-6.2M | 3.8M | -30.1M | -18.5M | 13M | 18.4M | 39.2M | 15.3M | -5.1M | 5.3M | 24.3M | 6.9M | 270K | |
74.2M | 70.4M | 100.5M | 117.4M | 104.4M | 86M | 47.6M | 32.3M | 36.6M | 31.3M | 7M | 135K | 0.0 | |
68M | 74.2M | 70.4M | 99M | 117.4M | 104.4M | 86.8M | 47.6M | 31.5M | 36.6M | 31.3M | 7M | 270K | |
-135.1M | -18.8M | 74.7M | -15M | -55.1M | -108.8M | 40.9M | -20.2M | -65.3M | -47.5M | 40.3M | -14.9M | -5.5M |
SEC Filings
VYGR - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | June 01, 2026 | June 01, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 07, 2026 | May 07, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | May 07, 2026 | March 31, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 28, 2026 | June 09, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 21, 2026 | April 15, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 09, 2026 | March 09, 2026 | 2026 | |
10-K 10-K 2025 FY FY | March 09, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | February 12, 2026 | February 09, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 08, 2026 | January 08, 2026 | 2026 | |
10-Q 10-Q 2025 Q3 Q3 | November 10, 2025 | September 30, 2025 | 2025 |
Related Guides
Continue your VYGR research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.